loading page

Prior use of therapeutic anticoagulation does not protect against COVID-19 related clinical outcomes in hospitalized patients: a propensity score-matched cohort study
  • +14
  • Janneke Spiegelenberg,
  • Marleen van Gelder,
  • Martje Maas,
  • marcel Hovens,
  • Anne Esselink,
  • Anton Dofferhoff,
  • Rob Janssen,
  • Josephine van de Maat,
  • Jacobien Hoogerwerf,
  • Nico Janssen,
  • Marianne van Apeldoorn,
  • Angèle Kerckhoffs,
  • Karin Veerman,
  • Marc Blaauw,
  • Robert Jan Hassing,
  • Kees Kramers,
  • Jenneke Leentjens
Janneke Spiegelenberg
Author Profile
Marleen van Gelder
Author Profile
Martje Maas
Bernhoven Hospital Location Uden
Author Profile
marcel Hovens
Hospital Rijnstate Arnhem
Author Profile
Anne Esselink
Canisius Wilhelmina Hospital
Author Profile
Anton Dofferhoff
Canisius Wilhelmina Ziekenhuis
Author Profile
Rob Janssen
Canisius Wilhelmina Ziekenhuis
Author Profile
Josephine van de Maat
Author Profile
Jacobien Hoogerwerf
Author Profile
Nico Janssen
Author Profile
Marianne van Apeldoorn
Jeroen Bosch Hospital
Author Profile
Angèle Kerckhoffs
Jeroen Bosch Ziekenhuis
Author Profile
Karin Veerman
Sint Maartenskliniek
Author Profile
Marc Blaauw
Author Profile
Robert Jan Hassing
Hospital Rijnstate Arnhem
Author Profile
Kees Kramers
Radboud Universiteit
Author Profile
Jenneke Leentjens
Author Profile


The hypercoagulable state observed in COVID-19 could be responsible for morbidity and mortality. In this retrospective study we investigated whether therapeutic anticoagulation prior to infection has a beneficial effect in hospitalized COVID-19 patients. 1154 COVID-19 patients admitted to 6 hospitals in the Netherlands between March and May 2020 were included. We applied 1:3 propensity score matching to evaluate the association between prior therapeutic anticoagulation use and clinical outcome, with in hospital mortality as primary endpoint. 190 (16%) patients used therapeutic anticoagulation prior to admission. In the propensity score matched analyses, we observed no associations between prior use of therapeutic anticoagulation and overall mortality (RR 1.02 (95% CI; 0.80-1.30) or length of hospital stay (7.0 [4-12] vs 7.0 {4-12] days, p=0.69), although we observed a lower risk of pulmonary embolism (RR 0.19 (95% CI; 0.05-0.80). This study shows that prior use of therapeutic anticoagulation is not associated with improved clinical outcome in hospitalized COVID-19 patients.

Peer review status:ACCEPTED

11 Jan 2021Submitted to British Journal of Clinical Pharmacology
12 Jan 2021Submission Checks Completed
12 Jan 2021Assigned to Editor
19 Jan 2021Reviewer(s) Assigned
16 Feb 2021Review(s) Completed, Editorial Evaluation Pending
23 Feb 2021Editorial Decision: Revise Major
21 Mar 20211st Revision Received
22 Mar 2021Submission Checks Completed
22 Mar 2021Assigned to Editor
22 Mar 2021Review(s) Completed, Editorial Evaluation Pending
11 Apr 2021Editorial Decision: Accept